Information Provided By: 
Fly News Breaks for April 3, 2017
UTHR, STDY
Apr 3, 2017 | 07:17 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for SteadyMed (STDY) to $15 after the Patent Trial and Appeal Board ruled in favor of the company in the IPR proceeding against United Therapeutics (UTHR). The ruling removes a "key layer of legal risk" around Trevyent's path to commercialization, Fein tells investors in a research note. He reiterates a Buy rating on SteadyMed.
News For STDY;UTHR From the Last 2 Days
There are no results for your query STDY;UTHR
